Aldeyra Therapeutics: Q4 Earnings Insights
Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
The Daily Biotech Pulse: AbbVie’s Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Aldeyra Therapeutics Earnings Preview
Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement.
Analysts estimate that Aldeyra Therapeutics will report an earnings per share (EPS) of $-0.28.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
55 Biggest Movers From Yesterday
Gainers
Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday.
Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Rite Aid Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 1.52% to 35,463.11 while the NASDAQ rose 2.10% to 15,295.45. The S&P also rose, gaining 1.55% to 4,638.74.
Mid-Day Market Update: Crude Oil Rises 3%; Aldeyra Therapeutics Shares Slide
Midway through trading Tuesday, the Dow traded up 1.15% to 35,332.22 while the NASDAQ rose 0.94% to 15,122.12. The S&P also rose, gaining 0.80% to 4,605.08.
Mid-Morning Market Update: Markets Open Higher; General Mills Earnings Miss Views
Following the market opening Tuesday, the Dow traded up 0.92% to 35,252.88 while the NASDAQ rose 0.57% to 15,067.01. The S&P also rose, gaining 0.63% to 4,596.62.
Citigroup Maintains Buy on Aldeyra Therapeutics, Lowers Price Target to $21
Citigroup analyst Yigal Nochomovitz maintains Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and lowers the price target from $25 to $21.